This study is to assess whether treatment with a therapeutic (100 mg) or supratherapeutic
(800 mg) dose of avanafil has the potential to cause QT/QTc prolongation in healthy
volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
VIVUS, Inc.
Collaborator:
Covance
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination